Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020
発行: GervanoRA Data Services LLP
ページ情報: 英文 157 Pages
GervanoRA's pipeline analysis and opportunity assessment report "Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020" analysed and assessed Uveal Melanoma pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Uveal Melanoma drugs industry.
The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Uveal Melanoma disease area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Uveal Melanoma drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type. The report has also highlighted the universities and institutes working on the development of new innovative therapeutics for the treatment of Uveal Melanoma.
Our comprehensive analysis on the Uveal Melanoma drug pipeline identified 53 drug candidates undergoing different stages of development- from Pre-clinical stage to Phase 3 stage. Among these, a total of 44 drug candidates are in clinical stages of development and 09 molecules are in non-clinical stage of development. The drug pipeline consists of four (4) pipeline molecules in late clinical stage of development (Phase III), and a total of 17 pipeline molecules in early clinical stage of development (Phase I).
The report has covered a total of 32 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.